Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation

NCT03146468 is registered in ClinicalTrials.gov with Melbourne Health as lead sponsor.

NCT NCT03146468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03146468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation
Lead sponsor
Melbourne Health
Phase
Phase 2
Overall status
Unknown status
Start date
May 8, 2017
Completion date
March 1, 2022
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

haematological malignancy